Atjaunināt sīkdatņu piekrišanu

E-grāmata: Intelligent Drug Development: Trials and Errors in Clinical Research

(Chief Consultant, Competitive Drug Development LLC)
  • Formāts: 240 pages
  • Izdošanas datums: 15-Apr-2014
  • Izdevniecība: Oxford University Press Inc
  • Valoda: eng
  • ISBN-13: 9780190200657
  • Formāts - PDF+DRM
  • Cena: 47,33 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
  • Formāts: 240 pages
  • Izdošanas datums: 15-Apr-2014
  • Izdevniecība: Oxford University Press Inc
  • Valoda: eng
  • ISBN-13: 9780190200657

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

Clinical research is heavily regulated and involves coordination of numerous pharmaceutical-related disciplines. Each individual trial involves contractual, regulatory, and ethics approval at each site and in each country. Clinical trials have become so complex and government requirements so stringent that researchers often approach trials too cautiously, convinced that the process is bound to be insurmountably complicated and riddled with roadblocks. A step back is needed, an objective examination of the drug development process as a whole, and recommendations made for streamlining the process at all stages.
With Intelligent Drug Development, Michael Tansey systematically addresses the key elements that affect the quality, timeliness, and cost-effectiveness of the drug-development process, and identifies steps that can be adjusted and made more efficient. Tansey uses his own experiences conducting clinical trials to create a guide that provides flexible, adaptable ways of implementing the necessary processes of development. Moreover, the processes described in the book are not dependent either on a particular company structure or on any specific technology; thus, Tansey's approach can be implemented at any company, regardless of size. The book includes specific examples that illustrate some of the ways in which the principles can be applied, as well as suggestions for providing a better context in which the changes can be implemented. The protocols for drug development and clinical research have grown increasingly complex in recent years, making Intelligent Drug Development a needed examination of the pharmaceutical process.

Recenzijas

Featured in the Journal of Clinical Research Best Practices, and selected for The First Clinical Research Bookshelf: Essential reading for clinical research professionals.

Acknowledgments vii
PART ONE Setting the Scene
Introduction: Cutting the Gordian Knot 3(6)
1 Aiming for Excellence
9(22)
PART TWO Planning: From Chaos to Cosmos
2 The Target Product Profile and Its Uses
31(16)
3 Planning the Individual Clinical Trial
47(10)
PART THREE The Practicable Protocol
4 Distilling the Essence of the Protocol: The Protocol Synopsis
57(11)
5 Redistillation: Eliminating Impurities by Carrying out Protocol Feasibility
68(22)
6 The Optimal Blend: The Approved Synopsis and the Final Protocol
90(13)
PART FOUR The Sponsor, The Physician, and The Patient: The Eternal Clinical Trial Triangle
7 Of Chickens and Eggs: The Sponsor's Dilemma
103(20)
8 Clinician or Clinical Trialist: The Physician's Dilemma
123(53)
9 What about the Customer? The Patient's Dilemma
176(11)
PART FIVE And Another Thing...
10 About Time: Making Meetings Matter
187(15)
11 The Brain-Scrambling, Fit-Inducing, Mind-Numbing Technicolor Laser Show
202(11)
References 213(4)
Index 217
Michael Tansey is former Vice President of La Jolla Pharmaceutical Company. He is currently an R&D consultant to pharmaceutical and biotechnology companies.